Interstitial Lung Disease Market Size was found to be more than USD 6 Billion in 2025 and It is projected to grow by 2036, estimates DelveInsight

DelveInsight's "Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Interstitial Lung Disease, historical and forecasted epidemiology as well as the Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Discover Key Insights into the Interstitial Lung Disease Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Interstitial Lung Disease Market Report
• The total number of Interstitial Lung Disease Diagnosed Prevalent Cases in the 7MM is ~1.3 million in 2025.
• According to DelveInsight's estimates, in 2025, the US reported nearly 520,000 diagnosed prevalent cases of Interstitial Lung Disease.
• According to DelveInsight analysis, in 2025, males represented about 44% of Interstitial Lung Disease cases in the US, whereas females accounted for roughly 56%.
• In 2025, sarcoidosis represented the most prevalent Interstitial Lung Disease subtype across EU4 and the UK, accounting for the largest share of diagnosed patients with approximately 180,000 cases, highlighting the significant contribution of inflammatory and immune-mediated lung disease to the regional Interstitial Lung Disease burden. This was followed by IPF with about 120,000 patients, underscoring the continued clinical and healthcare impact of progressive fibrotic Interstitial Lung Disease.
• DelveInsight's 2025 assessment highlights a modest gender disparity in Interstitial Lung Disease in Japan, with males accounting for approximately 52% of cases and females comprising about 48%. This near-balanced distribution suggests that while Interstitial Lung Disease slightly predominates in men-potentially reflecting higher exposure to occupational or environmental risk factors-the disease burden remains substantial in women, underscoring the need for gender-inclusive awareness, diagnosis, and management strategies.
• The number of treated Interstitial Lung Disease cases in the United States was about 420,000 in 2025 and is projected to increase by 2036.This upward trend highlights a steadily expanding treated population, reflecting both a rising underlying disease burden and improvements in diagnosis, treatment initiation, and long-term disease management across the US healthcare system.
• The leading Interstitial Lung Disease Companies such as United Therapeutics, Liquidia Corporation, Boehringer Ingelheim, Roche, GSK, Bristol-Myers Squibb and others.
• Promising Interstitial Lung Disease Therapies such as J2H P1905, CR405, APT-101, BLR-200, M-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, and others.

Stay ahead in the Interstitial Lung Disease Therapeutics Market with DelveInsight's Strategic Report @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interstitial Lung Disease Epidemiology Segmentation in the 7MM
• Interstitial Lung Disease Diagnosed Prevalent Cases
• Interstitial Lung Disease Gender-specific Cases
• Interstitial Lung Disease Type-specific Cases
• Interstitial Lung Disease Treated Cases

Download the report to understand which factors are driving Interstitial Lung Disease epidemiology trends @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interstitial Lung Disease Approved Therapies
• Treprostinil (TYVASO/TYVASO DPI/TREPROST): United Therapeutics
TYVASO and treprostinil (TYVASO DPI) are inhaled prescription therapies for adults with PAH (Group 1) and PH-Interstitial Lung Disease (Group 3). As a prostacyclin analogue, treprostinil promotes pulmonary vasodilation and inhibits platelet aggregation, improving exercise capacity. United Therapeutics reported in March 2026 that the Phase III TETON-1 trial assessing inhaled treprostinil achieved its primary endpoint in patients with idiopathic pulmonary fibrosis (IPF), indicating a notable improvement in lung function (FVC) and supporting the drug's potential to extend beyond PH-Interstitial Lung Disease into more general Interstitial Lung Disease indications. Positive outcomes from the Phase III TETON-2 trial in 2025 further demonstrated the safety and effectiveness of inhaled treprostinil in Interstitial Lung Disease, with steady improvements in lung function and no new safety signals, setting up the treatment for possible regulatory submission in populations with IPF and progressive fibrosing Interstitial Lung Disease Market.

Interstitial Lung Disease Pipeline Analysis
• Belimumab (BENLYSTA): GSK
Belimumab (BENLYSTA) is a B-lymphocyte Stimulator (BLyS)-specific inhibitor that binds to soluble BLyS, a key survival factor for B cells. As a fully human monoclonal antibody (mAb), belimumab inhibits BLyS-mediated prolonged B-cell survival, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. Belimumab (BENLYSTA) is currently under evaluation in late-stage (Phase II/III and Phase III) clinical trials for the treatment of SSc-Interstitial Lung Disease , and CTD-Interstitial Lung Disease reflecting increasing interest in B-cell-targeted immunomodulation to preserve lung function and slow fibrotic disease progression.

Interstitial Lung Disease Therapies and Key Companies
• J2H P1905: J2H Biotech
• CR405: Crystec Pharma
• APT-101: Apie Therapeutics
• BLR-200: BLR Bio
• M-156: ImmunoMet Therapeutics
• AD-214: AdAlta Limited
• Vixarelimab: Genentech
• Abatacept: Bristol-Myers Squibb
• HEC585: Sunshine Lake Pharma
• Efzofitimod: aTyr Pharma
• Pamrevlumab: FibroGen
• BI-1015550: Boehringer Ingelheim

Get In-Depth Knowledge on Interstitial Lung Disease Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interstitial Lung Disease Market Outlook
The expanding Interstitial Lung Disease treatment market is complemented by widely used supportive and background therapies, including corticosteroids, immunosuppressants, biologics, and adjunctive agents such as cough suppressants. In parallel, the emergence of next-generation pipeline therapies-including seralutinib, L606, N-115, and efzofitimod-is broadening the therapeutic landscape by targeting diverse disease mechanisms, sustaining long-term market growth and treatment innovation.

Scope of the Interstitial Lung Disease Market Report
• Study Period: 2022-2036
• Coverage: 7MM
• Key Interstitial Lung Disease Companies: United Therapeutics, Liquidia Corporation, Boehringer Ingelheim, Roche, GSK, Bristol-Myers Squibb and others.• Key Interstitial Lung Disease Therapies: J2H P1905, CR405, APT-101, BLR-200, M-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, and others
• Interstitial Lung Disease Therapeutic Assessment: Interstitial Lung Disease current marketed and Interstitial Lung Disease emerging therapies
• Interstitial Lung Disease Market Dynamics: Interstitial Lung Disease market drivers and Interstitial Lung Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Interstitial Lung Disease Unmet Needs, KOL's views, Analyst's views, Interstitial Lung Disease Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight's Comprehensive Interstitial Lung Disease Market Report @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Interstitial Lung Disease Market Report Introduction
2. Executive Summary for Interstitial Lung Disease
3. SWOT analysis of Interstitial Lung Disease
4. Interstitial Lung Disease Patient Share (%) Overview at a Glance
5. Interstitial Lung Disease Market Overview at a Glance
6. Interstitial Lung Disease Disease Background and Overview
7. Interstitial Lung Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Interstitial Lung Disease
9. Interstitial Lung Disease Current Treatment and Medical Practices
10. Interstitial Lung Disease Unmet Needs
11. Interstitial Lung Disease Emerging Therapies
12. Interstitial Lung Disease Market Outlook
13. Country-Wise Interstitial Lung Disease Market Analysis (2019-2032)
14. Interstitial Lung Disease Market Access and Reimbursement of Therapies
15. Interstitial Lung Disease Market Drivers
16. Interstitial Lung Disease Market Barriers
17. Interstitial Lung Disease Appendix
18. Interstitial Lung Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.